Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase III Trial to Assess the Efficacy and Safety of BupiZenge Compared to Lidocaine for Pain Associated With Oral Mucositis in Head and Neck Cancer

NCT07672236 is registered in ClinicalTrials.gov with OncoZenge AB as lead sponsor.

NCT NCT07672236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07672236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase III Trial to Assess the Efficacy and Safety of BupiZenge Compared to Lidocaine for Pain Associated With Oral Mucositis in Head and Neck Cancer
Lead sponsor
OncoZenge AB
Phase
Phase 3
Overall status
Recruiting
Start date
July 7, 2026
Completion date
January 31, 2027
Enrollment
150 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

head & neck cancer, oral mucositis